Analysis of Accuracy and Misdiagnosis of Controlled Attenuation Parameter in Evaluating Hepatic Steatosis in Patients with Chronic Hepatitis B

doi:10.7517/issn.1674-0475.230711

Abstract

Abstract: To explore the accuracy of controlled attenuation parameter (CAP) in assessing liver steatosis in chronic hepatitis B, and to analyze factors affecting the diagnostic accuracy of CAP. The clinical data of 215 patients with chronic hepatitis B were retrospectively collected, the diagnostic performance of CAP was analyzed using the receiver operating characteristic (ROC) curve, and the optimal cutoff value of CAP to evaluate different degrees of hepatic steatosis was obtained to distinguish different degrees of hepatic steatosis. To analyze the inconsistency between CAP and magnetic resonance proton density fat fraction (MRI-PDFF) in assessing the stage of hepatic steatosis. Logistic regression was used to analyze risk factors for CAP misdiagnosis. The results showed that in the entire study population, CAP had good diagnostic performance in diagnosing steatosis with or without steatosis, mild steatosis, and moderate to severe steatosis. According to the inconsistency in the diagnosis of steatosis stage between CAP and MRI-PDFF, patients were divided into a diagnostic consistency group and a diagnostic inconsistency group.Logistic regression results showed that age and BMI were independent risk factors for misdiagnosis of CAP. Although CAP has a certain misdiagnosis rate in assessing hepatic steatosis in chronic hepatitis B, it still has good diagnostic accuracy.

Key words: chronic hepatitis B, hepatic steatosis, controlled attenuation parameter, magnetic resonance imaging estimated proton density fat fraction, influencing factor

LU Jingnan, WANG Gailian, WEN Ya, SHA Wenxia. Analysis of Accuracy and Misdiagnosis of Controlled Attenuation Parameter in Evaluating Hepatic Steatosis in Patients with Chronic Hepatitis B[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2023, 41(6): 290-295.

References

[1] Hsu Y C, Huang D Q, Nguyen M H. Global burden of hepatitis B virus:Current status, missed opportunities and a call for action[J]. Nature Reviews Gastroenterology & Hepatology, 2023, 20(8):524-537.
[2] Li J, Zou B Y, Yeo Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019:A systematic review and meta-analysis[J]. The Lancet Gastroenterology & Hepatology, 2019, 4(5):389-398.
[3] Zheng Q, Zou B Y, Wu Y K, et al. Systematic review with meta-analysis:Prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Alimentary Pharmacology & Therapeutics, 2021, 54(9):1100-1109.
[4] Lee Y B, Ha Y, Chon Y E, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Clinical and Molecular Hepatology, 2019, 25(1):52-64.
[5] Liu L L, Li H, Zhang Y, et al. Hepatitis B virus infection combined with nonalcoholic fatty liver disease:Interaction and prognosis[J]. Heliyon, 2023, 9(1):e13113.
[6] 中国研究型医学院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等. 脂肪性肝病诊疗规范化的专家建议(2019年修订版) [J]. 临床肝胆病杂志, 2019, 35(11):2426-2430.
[7] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26(3):457-478.
[8] 王皓人, 张娜, 田梦圆, 等. 湘西少数民族地区血脂异常患病情况及其影响因素[J]. 中华疾病控制杂志, 2023, 27(4):431-436.
[9] Ye J Z, Wang W, Feng S T, et al. Precise fibrosis staging with shear wave elastography in chronic hepatitis B depends on liver inflammation and steatosis[J]. Hepatology International, 2020, 14(2):190-201.
[10] Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD[J]. Nature Reviews Endocrinology, 2022, 18(1):55-66.
[11] Jung J, Han A G, Madamba E, et al. Direct comparison of quantitative us versus controlled attenuation parameter for liver fat assessment using MRI proton density fat fraction as the reference standard in patients suspected of having NAFLD[J]. Radiology, 2022, 304(1):75-82.
[12] Wang J H, Ou H Y, Yen Y H, et al. Usefulness of controlled attenuation parameter in detecting and monitoring hepatic steatosis with MRI-PDFF as reference[J]. Digestive Diseases and Sciences, 2020, 65(5):1512-1519.
[13] Petroff D, Blank V, Newsome P N, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes:An individual patient data meta-analysis[J]. The Lancet Gastroenterology & Hepatology, 2021, 6(3):185-198.
[14] Sasso M, Audière S, Kemgang A, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan:A pilot study assessing diagnostic accuracy[J]. Ultrasound in Medicine and Biology, 2016, 42(1):92-103.
[15] de Lédinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis:A prospective study of 5323 examinations[J]. Journal of Hepatology, 2014, 60(5):1026-1031.
[16] Andrade P, Rodrigues S, Rodrigues-Pinto E, et al. Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease[J]. GE Portuguese Journal of Gastroenterology, 2016, 24(4):161-168.
[17] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志, 2018, 34(5):947-957.
[18] Kim D, Wijarnpreecha K, Sandhu K K, et al. Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States[J]. Liver International, 2021, 41(8):1832-1840.
[19] Sun X X, Liu Z L, Chen F Q, et al. Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults[J]. Scientific Reports, 2021, 11(1):15647.
[20] de Lédinghen V, Hiriart J B, Vergniol J, et al. Controlled attenuation parameter (CAP) with the XL probe of the fibroscan^®:A comparative study with the M probe and liver biopsy[J]. Digestive Diseases and Sciences, 2017, 62(9):2569-2577.
[21] Chan W K, Nik Mustapha N R, Lai-Hung Wong G, et al. Controlled attenuation parameter using the FibroScan^® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population[J]. United European Gastroenterology Journal, 2017, 5(1):76-85.